CN117427227B - Epsin1-Epsin2-shRNA functional gene coating stent and preparation method thereof - Google Patents
Epsin1-Epsin2-shRNA functional gene coating stent and preparation method thereof Download PDFInfo
- Publication number
- CN117427227B CN117427227B CN202311389181.7A CN202311389181A CN117427227B CN 117427227 B CN117427227 B CN 117427227B CN 202311389181 A CN202311389181 A CN 202311389181A CN 117427227 B CN117427227 B CN 117427227B
- Authority
- CN
- China
- Prior art keywords
- epsin
- shrna
- functional gene
- stent
- main body
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000004055 small Interfering RNA Substances 0.000 title claims abstract description 38
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 29
- 238000000576 coating method Methods 0.000 title claims abstract description 20
- 239000011248 coating agent Substances 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 102000007336 epsin Human genes 0.000 claims abstract description 58
- 108010032643 epsin Proteins 0.000 claims abstract description 58
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims abstract description 26
- 230000004663 cell proliferation Effects 0.000 claims abstract description 22
- 238000013508 migration Methods 0.000 claims abstract description 22
- 230000012292 cell migration Effects 0.000 claims abstract description 17
- 238000005406 washing Methods 0.000 claims abstract description 17
- 230000001737 promoting effect Effects 0.000 claims abstract description 12
- 239000000243 solution Substances 0.000 claims abstract description 12
- 239000007853 buffer solution Substances 0.000 claims abstract description 10
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 8
- 239000010410 layer Substances 0.000 claims abstract description 7
- 239000002356 single layer Substances 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- 238000007605 air drying Methods 0.000 claims description 9
- 238000004140 cleaning Methods 0.000 claims description 9
- 238000007654 immersion Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 239000012153 distilled water Substances 0.000 claims description 4
- DBLXOVFQHHSKRC-UHFFFAOYSA-N ethanesulfonic acid;2-piperazin-1-ylethanol Chemical compound CCS(O)(=O)=O.OCCN1CCNCC1 DBLXOVFQHHSKRC-UHFFFAOYSA-N 0.000 claims description 3
- 238000003860 storage Methods 0.000 claims description 3
- 230000002438 mitochondrial effect Effects 0.000 abstract description 17
- 230000003511 endothelial effect Effects 0.000 abstract description 8
- 206010061218 Inflammation Diseases 0.000 abstract description 4
- 230000004054 inflammatory process Effects 0.000 abstract description 4
- 230000036542 oxidative stress Effects 0.000 abstract description 3
- 210000003556 vascular endothelial cell Anatomy 0.000 abstract description 3
- 210000002889 endothelial cell Anatomy 0.000 description 42
- 210000004027 cell Anatomy 0.000 description 36
- 238000003197 gene knockdown Methods 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 239000008055 phosphate buffer solution Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 238000002513 implantation Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000002792 vascular Effects 0.000 description 8
- 210000001715 carotid artery Anatomy 0.000 description 7
- 208000006170 carotid stenosis Diseases 0.000 description 7
- 206010020718 hyperplasia Diseases 0.000 description 7
- 230000005012 migration Effects 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 208000037803 restenosis Diseases 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000002062 proliferating effect Effects 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 206010007687 Carotid artery stenosis Diseases 0.000 description 4
- 101100372758 Danio rerio vegfaa gene Proteins 0.000 description 4
- 102100030083 Epsin-2 Human genes 0.000 description 4
- 101710065000 Epsin-2 Proteins 0.000 description 4
- 108020004459 Small interfering RNA Proteins 0.000 description 4
- 101150030763 Vegfa gene Proteins 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 210000003470 mitochondria Anatomy 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 208000019553 vascular disease Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 210000001168 carotid artery common Anatomy 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 239000011247 coating layer Substances 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000012192 staining solution Substances 0.000 description 3
- 239000012096 transfection reagent Substances 0.000 description 3
- 239000012224 working solution Substances 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 208000032382 Ischaemic stroke Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000002583 angiography Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 210000000269 carotid artery external Anatomy 0.000 description 2
- 210000004004 carotid artery internal Anatomy 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000002121 endocytic effect Effects 0.000 description 2
- 230000010595 endothelial cell migration Effects 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 230000004992 fission Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000015590 smooth muscle cell migration Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000010867 Carotid Artery injury Diseases 0.000 description 1
- 208000014882 Carotid artery disease Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 101000975428 Homo sapiens Inositol 1,4,5-trisphosphate receptor type 1 Proteins 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- 102100024039 Inositol 1,4,5-trisphosphate receptor type 1 Human genes 0.000 description 1
- 208000034827 Neointima Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 description 1
- 101710202113 Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 241001655322 Streptomycetales Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 208000037876 carotid Atherosclerosis Diseases 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000013152 interventional procedure Methods 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000011201 multiple comparisons test Methods 0.000 description 1
- AFRBPRLOPBAGCM-UHFFFAOYSA-N n-[2-(1h-indol-4-yl)ethyl]-n-propylpropan-1-amine Chemical compound CCCN(CCC)CCC1=CC=CC2=C1C=CN2 AFRBPRLOPBAGCM-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000004963 pathophysiological condition Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000004026 tunica intima Anatomy 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/258—Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/42—Anti-thrombotic agents, anticoagulants, anti-platelet agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
- A61L2300/608—Coatings having two or more layers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/02—Methods for coating medical devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/08—Coatings comprising two or more layers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention discloses Epsin-Epsin-shRNA functional gene coating bracket and a preparation method thereof. Wherein Epsin-Epsin 2-shRNA functional gene coating stent is characterized in that: comprises a bracket main body and Epsin-Epsin-shRNA functional gene coating, wherein the Epsin 1-Epsin-shRNA functional gene coating is coated on the surface of the bracket main body; the preparation method of the bracket comprises the following steps: immersing the stent body in a PrS solution; taking out the bracket main body, and washing with buffer solution; immersing the stent main body taken out in the second step into Epsin-Epsin-shRNA solution; repeating the washing in the second step; repeating the operations from the first step to the fourth step for twelve times to form a single-layer ion layer. The invention explores the application of Epsin protein in inhibiting vascular endothelial cell proliferation, and finds that Epsin knockdown indirectly inhibits smooth muscle cell proliferation and migration by promoting endothelialization, reducing endothelial inflammation and mitochondrial oxidative stress.
Description
Technical Field
The invention belongs to the technical field of vascular stents, and particularly provides a Epsin <1 > -Epsin < 2 > -shRNA functional gene coating stent.
Background
With the aging of the social population, cerebrovascular diseases are becoming a leading cause of death worldwide. Among these cerebrovascular diseases, ischemic stroke is the highest, with about 15-20% of ischemic strokes being due to carotid atherosclerosis and carotid stenosis. Due to the low risk of injury in intravascular interventions, few surgical complications, interventional procedures have become one of the main approaches to treat such diseases. However, neointimal hyperplasia (IH) can lead to restenosis of the lumen, leading to failure of angioplasty. Without preventive intervention, the incidence of restenosis would reach 30-50% within 6 months after surgery. The occurrence of neointimal hyperplasia thus severely affects the long-term efficacy and safety of carotid stenting. The current drugs for preventing stenosis, such as rapamycin (sirolimus) and paclitaxel, applied to drug-coated stents, all prevent neointimal thickening by inhibiting smooth muscle cell proliferation and migration. However, these drugs do not selectively inhibit proliferation, migration of smooth muscle cells and endothelial cells, and cause long-term damage to endothelial cells. Endothelial cells have reduced proliferative migration capacity and the damaged vessel cannot be endothelialized in time, resulting in a greatly increased risk of late thrombosis and late restenosis.
Endothelial dysfunction and endothelial cell loss are also one of the causes of neointimal hyperplasia. If endothelialization is rapid after stent implantation, neointima will be reduced and the risk of post-stent stenosis and late stent thrombosis will be significantly reduced. In addition, rapid regeneration of the endothelium and protection of endothelial cell function may also indirectly inhibit proliferation and migration of SMC to reduce intimal hyperplasia. Thus, protecting endothelial cells functions plays an important role in preventing restenosis.
Drug eluting stents and drug eluting balloons are currently used to reduce neointimal hyperplasia by inhibiting smooth muscle cell proliferation. However, these antiproliferative agents also inhibit endothelial cell growth, resulting in delayed endothelial healing. Long-term clinical studies of stents or balloons employing these drugs often report cases of vascular Smooth Muscle Cell (SMC) fibrosis and advanced stent thrombosis, which raise concerns about the clinical application prospects of these drug eluting stents and drug eluting balloons.
The family of growth regulatory proteins (Epsin) proteins is known for their role as highly conserved, membrane-associated, ubiquitin-binding endocytic adaptors, exhibiting high specificity in binding protein selection. Under different pathophysiological conditions, their expression in different cells is different. In the context of atherosclerosis, epsin and Epsin 2 are expressed in endothelial cells and macrophages. Epsin interact with IP3R1 in endothelial cells and bind to LRP-1 in macrophages. Epsin have therapeutic potential.
Disclosure of Invention
In order to achieve the aim, the invention provides a Epsin-Epsin 2-shRNA functional gene coated stent, which comprises a stent main body and a Epsin 1-Epsin 2-shRNA functional gene coating, wherein the Epsin 1-Epsin 2-shRNA functional gene coating is coated on the surface of the stent main body.
The preparation method of Epsin-Epsin-shRNA functional gene coating stent comprises the following steps:
Step one, immersing a stent body in PrS solution;
Step two, taking out the bracket main body, and washing with buffer solution;
Step three, immersing the stent main body taken out in the step two into Epsin <1 > -Epsin < 2 > -shRNA solution;
Step four, repeating the washing in the step two;
step five, repeating the operations from the step one to the step four for twelve times, and forming a single-layer ion layer each time, so that twelve layers Epsin-Epsin 2-shRNA coatings are coated on the surface of the bracket main body;
And step six, cleaning and air-drying the support main body, and placing the support main body into a dryer at room temperature for storage.
Further, the immersion time in the first step is 6 to 10 minutes, most preferably 8 minutes.
Further, the buffer solution in the second step is HEPES (4-hydroxyethyl piperazine ethane sulfonic acid) buffer solution, and the washing process is repeated three times for 1-2 minutes, and most preferably 1 minute.
Further, the immersion time in step three is 6 to 10 minutes, most preferably 8 minutes.
Further, in the step six, cleaning and air-drying are performed by using three distilled water, and air-drying is performed by using nitrogen.
The beneficial effects of using the invention are as follows:
exploring the use of Epsin protein expression inhibition in inhibiting vascular endothelial cell proliferation, epsin knockdown was found to indirectly inhibit smooth muscle cell proliferation and migration by promoting endothelialization, reducing endothelial inflammation and mitochondrial oxidative stress;
epsin 1-Epsin-shRNA functional genes are used as coating layers of vascular stents, so that the risks of late thrombosis and late restenosis after vascular stent implantation are reduced.
Drawings
FIG. 1 is a schematic image of carotid Epsin expression after 7 days in each group;
FIG. 2 is a graph showing statistics of carotid Epsin expression after 7 days in each group of mice;
FIG. 3 is a graphical representation of the effect of knockdown Epsin on endothelial cell proliferation;
FIG. 4 is a statistical plot of the number of effects of knockdown Epsin on endothelial cell proliferation;
FIG. 5 is a schematic image of the effect of knockdown Epsin on endothelial cell migration;
FIG. 6 is a statistical plot of the number of effects of knockdown Epsin on endothelial cell migration;
FIG. 7 is a graphical representation of the effect of knockdown Epsin on endothelial cell mitochondrial morphology;
FIG. 8 is a statistical plot of the number of knockdown Epsin effects on endothelial cell mitochondrial morphology;
FIG. 9 is a graphical representation of the effect of knockdown Epsin on endothelial cell mitochondrial potential;
FIG. 10 is a statistical plot of the number of effects of knockdown Epsin on endothelial cell mitochondrial potential;
FIG. 11 is a graphical representation of the effect of knockdown Epsin endothelial cells on smooth muscle cell proliferation co-cultured therewith;
FIG. 12 is a statistical plot of the number of effects of knockdown Epsin endothelial cells on smooth muscle cell proliferation co-cultured therewith;
FIG. 13 is a graphical representation of the effect of knockdown Epsin endothelial cells on smooth muscle cell migration in co-culture therewith;
FIG. 14 is a statistical plot of the effect of knockdown Epsin endothelial cells on smooth muscle cell migration in co-culture therewith;
FIG. 15 is a graphical representation of transfection efficiency of each group 7 days after stent implantation and 28 days after stent implantation;
FIG. 16 is a schematic image of the surface features of each set 7 days after and 28 days after stent implantation;
FIG. 17 is a schematic image of intimal hyperplasia in each group 7 days and 28 days after stent implantation;
Detailed Description
The present invention will be described in detail below with reference to the accompanying drawings.
Example 1
Inhibition Epsin of protein expression can play a role in inhibiting proliferation of vascular intima;
Epsin-shRNA is used as a functional coating to be applied to a vascular stent, so that the effects of inhibiting migration and proliferation of vascular endothelial cells and smooth cells are achieved, and the purposes of reducing late thrombosis and late restenosis risk after implantation of the vascular stent are achieved.
Epsin proteins are specifically Epsin and Epsin.
Example two
Specifically, the experimental method and experimental procedure are as follows:
1. Experimental animals and groups
The study purchased 12 healthy clean male C57BL/6J mice weighing around 24g from the north battlefield general hospital medical laboratory animal center, animals were randomly divided into 2 groups: the animal model was constructed with carotid stenosis model group (injury) (n=6) and sham operation group (sham) (n=6).
2. Method of
2.1 Preparation of a mouse carotid stenosis model
C57BL/6J mice were anesthetized with a syringe to extract 1% sodium pentobarbital at a concentration of 50mg/kg by intraperitoneal injection. The fully anesthetized mice were placed on an operating table, the mice were fixed in a supine position, and the razor was used to remove hair around the neck surgical incision and thoroughly disinfect the neck skin. The mice were placed on a 37℃thermostat to maintain their body temperature stable and monitored for stability. Towel around the incision, operate under surgical microscope, adjust the focal length of the microscope, gently separate left cervical tissue with atraumatic microshutter, left common carotid artery (common carotid artery, CCA), external carotid artery (External carotid artery, ECA), and internal carotid artery (internal carotid artery, ICA). In the process, bleeding is avoided as much as possible, the tail end of the left common carotid artery is ligated, and the skin is sewn. The operation of the false operation group is consistent with the operation method of the carotid artery stenosis model except the ligation of the carotid artery on the left side, the mice are sent back to the observation state of the animal room after being awakened, and the materials are obtained after 7 days.
2.2 Materials of study object
After the carotid artery ligation model is successfully manufactured for 7 days, 1% concentration pentobarbital sodium is extracted by a syringe according to the proportion of 50mg/kg, the mice are anesthetized by an intraperitoneal injection mode, after the mice are in a complete anesthetic state, the mice are fixed on an operation table in a supine position, hairs at the incision are removed by a razor, neck skin is fully disinfected by soaking with a cotton swab or a medical cotton ball, the skin is cut open, the skin is taken out, the carotid arteries of the mice are rapidly separated under a stereoscopic microscope, and the separated carotid arteries of the mice are respectively put into liquid nitrogen and paraformaldehyde for preservation.
2.3 Cell culture
Cell culture the cells were periodically observed with a microscope using DMEM (Dulbecco's modified eagle medium) medium containing 10% fbs under constant cell culture conditions at 5% co 2 at 37 ℃ and were replaced, passaged and frozen at intervals according to the cell growth conditions, as required for the experiment.
2.4 Passage of cells
When the cells are close to the overgrown cell culture dish, the culture medium in the cell culture dish is sucked out, the PBS (phosphate buffer solution) is used for lightly cleaning the culture medium for three times, the residual culture medium is cleaned, the prepared pancreatin is added for digestion, when the cells are fully digested, the culture medium with serum is added for stopping digestion, 500r and 5min are centrifuged, the supernatant is discarded, the culture medium containing the serum is added for blowing and evenly mixing, and then the cells are transferred into a new culture dish.
2.5 Treatment of laboratory cells
The following groupings were formed by transfecting human umbilical vein endothelial cells with siRNA, after VEGF (vascular endothelial growth factor) (50 μm) stimulation and PBS, respectively, for 24 hours: si control (blank), siEpsin1+ siEpsin2, si control+vegf, siEpsin1+ siEpsin2+vegf. The siRNA transfection is to culture the cells first, and a proper amount of cells are taken one day before transfection and inoculated into a six-hole plate or other containers for cell experiments, and the method takes a 6-hole plate as an example, so that the cell density of a culture dish can reach about 50-70% in the next day, cells are intermittently observed, and when the cells grow to a proper density, the transfection is started. Taking two clean and sterile tubes, respectively adding 150 mu l of culture medium without antibiotics and serum into the two EP tubes, then adding siRNA into one tube, and lightly blowing and uniformly mixing by using a gun; while the other tube was filled with 6. Mu.l Lipo 2000 transfection reagent, gently stirred with a gun and allowed to stand at room temperature for 5min. The siRNA-containing medium was gently added to Lipo 2000 transfection reagent-containing medium with a pipette, followed by gently pipetting and mixing, and allowed to stand at room temperature for 15min, at which time the six well plates with cells cultured were washed three times with PBS per well. The transfection reagent was mixed with 700. Mu.l serum-free antibiotic-free medium and added to a 6-well plate.
2.6 Cell cryopreservation
The cell digestion process is consistent with the cell passage method, the upper liquid of the cells is removed after centrifugation, the prepared cell freezing solution (900 mu l of serum and 100 mu l of dimethyl sulfoxide) is added, the cells are resuspended, the cell freezing tube is added, and the cell freezing tube is put into liquid nitrogen for preservation. And taking out the cells when the cells need to be recovered.
2.7 Paraffin section
The carotid artery of the mice fixed with paraformaldehyde is taken out, washed with water, dehydrated with 70% alcohol, 80% alcohol, 90% alcohol and 95% alcohol in sequence for 5min to 10min, and finally placed into xylene for transparency. Immersing the tissue in paraffin, cooling, slicing, taking the cut tissue slice when the tissue slice is cut to a designated position, spreading, and water-bathing. The tissue was fixed to the slide by baking after scooping up the slide.
2.8 HE staining
The tissue sections were dewaxed sequentially with xylene, 9 5% alcohol, 90% alcohol, 80% alcohol, 70% alcohol, distilled water, stained with hematoxylin for 5min, and rinsed with running water. Adding eosin for dyeing, washing off the dyeing agent with running water, sequentially dehydrating with 70% alcohol, 80% alcohol, 90% alcohol, 9 5% alcohol and xylene, and sealing with neutral resin.
2.9 Immunohistochemistry
The dewaxing step is consistent with the HE staining step, according to an immunohistochemical kit, firstly adding a peroxidase blocker for 10min, washing with PBS for 3 times, adding non-immune animal serum for sealing for 10min, incubating with a primary antibody overnight, rewarming, adding a drop of biotin-marked secondary antibody, washing with PBS (phosphate buffer solution) for 3 times, adding streptomycete biotin-peroxidase for 10min, washing for 3 times, developing with DAB solution, and paying attention to the staining time to avoid over-deep or over-shallow color.
2.10 Mitochondrial staining and JC-1 staining
Mito-Tracker: after treatment of the cells, when the cells were cultured in a cell culture plate or dish to a certain time point, mito-Tracker working solution was added according to the instructions and incubated at 37℃for 30min. Mito-Tracker working solution was removed, washed 3 times with PBS, and cell culture medium was added. Observations were made with a microscope.
JC-1: when each group of cells reached the experimental target time point, JC-1 staining working solution was added according to the instruction, and incubated in a cell incubator at 37℃for 20min. After the incubation, the staining solution was removed and the JC-1 staining buffer was washed 2 times. Cell culture medium was added and observed under a microscope.
2.11 Cell migration
Endothelial cells and smooth cell migration were analyzed by wound healing assay. Cells were spread to an appropriate density, endothelial cells and smooth muscle cells were uniformly injured using a pipette tip having a diameter of 1.15 mm, a standard photograph of the wound area was taken by a microscope, and a picture of the wound site was taken again after 24 hours. The distance traveled by the wound cells was calculated by subtracting the distance of the 24h lesion edge from the distance of the 0h lesion edge.
2.12 Co-culture model of endothelial cells and smooth muscle cells
Endothelial cells were incubated 24 h with smooth muscle cells using a Transwell chamber (0.4 μm), the smooth muscle cells were placed in the lower chamber and the endothelial cells were placed in the upper chamber. After 3 times of PBS washing, VSMC (smooth muscle cell) proliferation and migration indexes were detected.
2.13 Immunofluorescence
Cell seeds were washed 3 times in a cover glass in PBS (phosphate buffer solution), punched with Triton X-100 at a concentration of 0.1%, washed 3 times with PBS after 30min, blocked with goat serum for 2h, incubated overnight on the cells in a 4 degree refrigerator using a prepared primary antibody solution dropwise, washed 3 times with PBS, incubated with a fluorescent secondary antibody for 2h, washed 3 times with PBS, incubated for 5min with a staining solution (preferably a staining solution of DPAI), and blocked. And observing by using a fluorescence microscope.
2.14, Preparation of Experimental materials
Two sets of vascular stents were prepared and shControl and shEpsin1+ Epsin2 were coated on the two sets of vascular stents, respectively.
2.15 Observing males
About 30kg of male Bama pigs were taken and stented into carotid arteries, divided into shControl and shEpsin1+ Epsin2 groups: detection by pathological tissue morphology analysis.
2.16 Statistical analysis
Statistical analysis was performed using GRAPHPAD PRISM V9.0.0 and chart making was performed. All data were analyzed using One-way ANOVA and the differences between groups were compared using multiple comparisons (Tukey's multiple comparisons tests), P <0.05 indicating that the differences were statistically significant.
3. Experimental results
3.1, To evaluate Epsin expression level changes during formation of carotid artery stenosis in mice, the experiment showed that Epsin was significantly elevated in immunohistochemical levels compared to sham mice by day 7 in both sham mice and carotid artery ligation model group mice, indicating that Epsin expression was increased in the mouse carotid artery stenosis model, epsin had a positive correlation with carotid artery stenosis in mice. Has statistical significance (P < 0.05), and is shown in FIGS. 1 and 2.
3.2, Based on the clear Epsin positive correlation with proliferative vascular disease, to further explore the specific mechanism by which Epsin plays a role in proliferative vascular disease, this study was performed by subjecting endothelial cells to four different treatments, siControl, siEpsin1+ siEpsin2, sicontrol+vegf, siEpsin1+ siEpsin 2+vegf. Due to the similarity of Epsin and Epsin2 functions, knockdown Epsin results in increased Ki67 expression levels in endothelial cells, longer relative migration distances, and knockdown Epsin promotes endothelial cell proliferation and migration, which is also the first step in ensuring early endothelialization after vascular injury. See fig. 3,4, 5 and 6 for details.
3.3, Further studies indicate that knockdown Epsin stabilizes endothelial cell function by maintaining mitochondrial homeostasis. Mitochondrial performance (especially mitochondrial fission) in endothelial cells is significantly regulated by mitochondrial dynamics. Thus, we investigated whether knock-down Epsin protects endothelial cells from mitochondrial dysfunction by alleviating mitochondrial fission. By observing the mitochondrial morphology through immunofluorescence, epsin knockdown obviously increases the area of mitochondria in endothelial cells and increases the activity of endothelial cells. Meanwhile, epsin knockdown protects the mitochondrial potential homeostasis of endothelial cells and maintains the stability of endothelial cells. See fig. 7, 8, 9 and 10 for details.
3.4, We found that knock-down Epsin endothelial cells indirectly inhibited smooth muscle cell proliferation and migration. See fig. 11, 12, 13 and 14 for details.
3.5 HUVECs were seeded onto scaffolds and transfection of these cells was observed under confocal laser scanning microscopy. It is blue, indicating that the cells on the scaffold are evenly distributed and almost completely covered. Some cells fluoresce green, indicating that they have been transfected.
The scaffold was examined with a scanning electron microscope. No metal support, smooth surface and no fittings. The machined support surface coating is uniform.
Example III
To directly evaluate Epsin-shRNA functional coated scaffolds, the functional coated scaffolds were compared to shRNA groups and Epsin-shRNA functional coated scaffold groups. At 1 week (W) and 1 month (M), the samples were observed and analyzed. Angiography was performed 15 minutes after successful implantation to confirm that the cavity was clear, free of filling defects, vessel wall dissection, embolism, stent displacement or distal vasospasm. There were no significant differences in heart rate, blood pressure and body weight in the preoperative, intraoperative and follow-up angiography groups. No obvious abnormal behavior, diet and defecation after operation.
Histomorphology analysis
Hematoxylin-eosin (he) staining images showed that shEpsin stent groups formed a monolayer of endothelial cells on shEpsin stents on days 7 and 7 after 1 month of stent implantation, whereas the control group was directly exposed to blood. After one month, shEpsin stent groups showed less intimal hyperplasia than the control group, figures 15, 16, 17.
In this study, proliferation and migration of endothelial cells was increased, which is the first step required for endothelialization, while we found that Epsin and 2 endocytic adaptor proteins play a novel role in division of mitochondria by endothelial cells, which is common in proliferative vascular diseases such as restenosis following carotid artery injury. Endothelial mitochondrial volume is one of the main mechanisms responsible for abnormal proliferation of blood vessels; however, the underlying molecular mechanisms remain elusive. Plays a key role in the widely accepted model of "endothelial injury". Knock down Epsin reduces mitochondrial division in endothelial cells. Maintains membrane potential steady state of mitochondria, protects activity of mitochondria, and maintains relative stability of endothelial cells.
Meanwhile, we found that Epsin knockdown indirectly inhibited smooth muscle cell proliferation and migration by promoting endothelialization, reducing endothelial inflammation and mitochondrial oxidative stress. Provides a new target for treating the proliferative vascular diseases.
Targeting Epsin to VEGFR2 in endothelial cells has shown promise in the treatment of various cancers. In the mouse model of atherosclerosis, it reduces activation of endothelial NF- κB and reduces endothelial inflammation. Also, recent studies have found that inhibition Epsin can promote the formation of a monolayer of endothelium on the surface of vascular grafts.
Example IV
Epsin 1-Epsin 2-shRNA functional gene coating stent comprises a stent main body and Epsin 1-Epsin-shRNA functional gene coating layers, wherein Epsin 1-Epsin 2-shRNA functional gene coating layers are coated on the surface of the stent main body.
Examples
Specifically, the preparation method of Epsin-Epsin 2-shRNA functional gene coating stent comprises the following steps:
Step one, immersing a stent body in PrS solution;
Step two, taking out the bracket main body, and washing with buffer solution;
step three, immersing the stent main body taken out in the step two into Epsin to Epsin-shRNA solution (the solution is a reagent which can be purchased in the market);
Step four, repeating the washing in the step two;
step five, repeating the operations from the step one to the step four for twelve times to form a single-layer ion layer each time, so that twelve layers Epsin-Epsin 2-shRNA coatings are coated on the surface of the stent main body;
And step six, cleaning and air-drying the support main body, and placing the support main body into a dryer at room temperature for storage.
Specifically, the immersion time in the first step is 6 to 10 minutes, and most preferably 8 minutes;
The buffer solution in the second step is HEPES (4-hydroxyethyl piperazine ethane sulfonic acid) buffer solution, and the washing process is repeated for three times, wherein the time length of each time is 1-2 minutes, and most preferably 1 minute;
the immersion time in the third step is 6-10 minutes, most preferably 8 minutes;
And step six, cleaning and air-drying, namely cleaning by using triple distilled water and air-drying by using nitrogen.
The foregoing is merely exemplary of the present invention, and many variations may be made in the specific embodiments and application scope of the invention by those skilled in the art based on the spirit of the invention, as long as the variations do not depart from the gist of the invention.
Claims (9)
1. Epsin 1-Epsin-shRNA functional gene coated stent for promoting endothelialization and inhibiting smooth muscle cell proliferation and migration, characterized in that: comprises a bracket main body and Epsin-Epsin-shRNA functional gene coating, wherein the Epsin-Epsin-shRNA functional gene coating is coated on the surface of the bracket main body.
2. The preparation method of Epsin-Epsin-shRNA functional gene coating stent for promoting endothelialization and inhibiting smooth muscle cell proliferation and migration comprises the following steps:
Step one, immersing a stent body in PrS solution;
Step two, taking out the bracket main body, and washing with buffer solution;
Step three, immersing the stent main body taken out in the step two into Epsin <1 > -Epsin < 2 > -shRNA solution;
Step four, repeating the washing in the step two;
step five, repeating the operations from the step one to the step four for twelve times, and forming a single-layer ion layer each time, so that twelve layers Epsin-Epsin 2-shRNA coatings are coated on the surface of the bracket main body;
And step six, cleaning and air-drying the support main body, and placing the support main body into a dryer at room temperature for storage.
3. The method for preparing the Epsin-Epsin-shRNA functional gene-coated stent for promoting endothelialization to inhibit smooth muscle cell proliferation and migration according to claim 2, wherein the method comprises the following steps: the immersion time in the first step is 6-10 minutes.
4. The method for preparing the Epsin-Epsin-shRNA functional gene-coated stent for promoting endothelialization to inhibit smooth muscle cell proliferation and migration according to claim 3, wherein the method comprises the following steps: the immersion time in the first step was 8 minutes.
5. The method for preparing the Epsin-Epsin-shRNA functional gene-coated stent for promoting endothelialization to inhibit smooth muscle cell proliferation and migration according to claim 2, wherein the method comprises the following steps: and the buffer solution in the second step is HEPES (4-hydroxyethyl piperazine ethane sulfonic acid) buffer solution, and the washing process is repeated for three times, wherein the time duration is 1-2 minutes.
6. The method for preparing the Epsin-Epsin-shRNA functional gene coated stent for promoting endothelialization to inhibit smooth muscle cell proliferation and migration according to claim 5, wherein the method comprises the following steps: the duration of each washing process in the second step is 1 minute.
7. The method for preparing the Epsin-Epsin-shRNA functional gene-coated stent for promoting endothelialization to inhibit smooth muscle cell proliferation and migration according to claim 2, wherein the method comprises the following steps: the immersion time in the third step is 6-10 minutes.
8. The method for preparing the Epsin-Epsin-shRNA functional gene coated stent for promoting endothelialization to inhibit smooth muscle cell proliferation and migration according to claim 7, wherein the method comprises the following steps: the immersion time in the third step was 8 minutes.
9. The method for preparing the Epsin-Epsin-shRNA functional gene-coated stent for promoting endothelialization to inhibit smooth muscle cell proliferation and migration according to claim 2, wherein the method comprises the following steps: and step six, cleaning and air-drying, namely cleaning by using triple distilled water and air-drying by using nitrogen.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311389181.7A CN117427227B (en) | 2023-10-25 | 2023-10-25 | Epsin1-Epsin2-shRNA functional gene coating stent and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311389181.7A CN117427227B (en) | 2023-10-25 | 2023-10-25 | Epsin1-Epsin2-shRNA functional gene coating stent and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117427227A CN117427227A (en) | 2024-01-23 |
CN117427227B true CN117427227B (en) | 2024-06-11 |
Family
ID=89551011
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311389181.7A Active CN117427227B (en) | 2023-10-25 | 2023-10-25 | Epsin1-Epsin2-shRNA functional gene coating stent and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117427227B (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003257624A1 (en) * | 2002-08-20 | 2004-03-11 | Terumo Kabushiki Kaisha | Medical instrument to be implanted in the body |
CN101002968A (en) * | 2007-01-23 | 2007-07-25 | 重庆大学 | Intravascular stent carried with double gene, and its preparing method |
WO2009116750A2 (en) * | 2008-03-17 | 2009-09-24 | 이화여자대학교 산학협력단 | Composition for the coating of stent for preventing restenosis and stent manufactured using same |
CN103083734A (en) * | 2013-01-23 | 2013-05-08 | 浙江大学 | Preparation method of cardiovascular stent loaded with functional gene coat, and bracket obtained therefrom |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040213826A1 (en) * | 2003-04-28 | 2004-10-28 | Marx Steven O. | Medical devices and methods for inhibiting proliferation of smooth muscle cells |
GB0321694D0 (en) * | 2003-09-16 | 2003-10-15 | Ark Therapeutics Ltd | Genes and their therapeutic use |
CN115089773A (en) * | 2022-07-19 | 2022-09-23 | 中国科学院长春应用化学研究所 | Intravascular stent bionic coating, intravascular stent and preparation method thereof |
-
2023
- 2023-10-25 CN CN202311389181.7A patent/CN117427227B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003257624A1 (en) * | 2002-08-20 | 2004-03-11 | Terumo Kabushiki Kaisha | Medical instrument to be implanted in the body |
JP2010155095A (en) * | 2002-08-20 | 2010-07-15 | Terumo Corp | Medical instrument to be implanted in the body |
CN101002968A (en) * | 2007-01-23 | 2007-07-25 | 重庆大学 | Intravascular stent carried with double gene, and its preparing method |
WO2009116750A2 (en) * | 2008-03-17 | 2009-09-24 | 이화여자대학교 산학협력단 | Composition for the coating of stent for preventing restenosis and stent manufactured using same |
CN103083734A (en) * | 2013-01-23 | 2013-05-08 | 浙江大学 | Preparation method of cardiovascular stent loaded with functional gene coat, and bracket obtained therefrom |
Non-Patent Citations (2)
Title |
---|
Epsin Mimetic UPI Peptide Delivery Strategies to Improve Endothelization of Vascular Grafts;Changizi S, et al;Macromolecular bioscience;20230428;第9卷(第23期);摘要和第2页第1栏第3段 * |
药物洗脱支架和内皮细胞种植支架的生物相容性;武清敏;乔钦增;赵卫林;王立峰;张永红;郭全合;常增义;;中国组织工程研究与临床康复;20080826(35);全文 * |
Also Published As
Publication number | Publication date |
---|---|
CN117427227A (en) | 2024-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Fairbairn et al. | The clinical applications of human amnion in plastic surgery | |
JP6449220B2 (en) | New hair follicle | |
CN105477016A (en) | Application of exosome derived from human mesenchymal stem cells to resistance to tissue fibrosis and scar forming | |
Shojaati et al. | Compressed collagen enhances stem cell therapy for corneal scarring | |
Guo et al. | Grafting of mesenchymal stem cell-seeded small intestinal submucosa to repair the deep partial-thickness burns | |
Gardien et al. | Progress towards cell-based burn wound treatments | |
US9840704B2 (en) | Molecular targets for the prevention and/or treatment of fibrosis, hypertrophic scars or keloids | |
US11946051B2 (en) | Composition for preventing or treating keloids or hypertrophic scars | |
Zhang et al. | ERK2 small interfering RNAs prevent epidural fibrosis via the efficient inhibition of collagen expression and inflammation in laminectomy rats | |
Szabó et al. | Antifibrotic effect of mitomycin‐C on human vocal cord fibroblasts | |
Zhang et al. | Autologous adipose tissue–derived mesenchymal stem cells introduced by biliary stents or local immersion in porcine bile duct anastomoses | |
Dolivo et al. | A dehydrated, aseptically-processed human amnion/chorion allograft accelerates healing in a delayed murine excisional wound model | |
JP5372764B2 (en) | Materials and methods for the treatment and management of angiogenesis-related diseases | |
JP6918003B2 (en) | Stem cells for wound healing | |
Mao et al. | An in vitro comparison of human corneal epithelial cell activity and inflammatory response on differently designed ocular amniotic membranes and a clinical case study | |
Cao et al. | Dedicator of cytokinesis 2 silencing therapy inhibits neointima formation and improves blood flow in rat vein grafts | |
CN117427227B (en) | Epsin1-Epsin2-shRNA functional gene coating stent and preparation method thereof | |
JP2010509228A5 (en) | ||
CN110575540A (en) | use of PDGF inhibitors for the production of a medicament for the treatment of inflammatory intestinal diseases | |
KR20160000030A (en) | Pharmaceutical adjuvant composition for treating damages of skin or blood vessel tissue | |
CN110261598B (en) | Application of eEF2K in screening of drug targets for promoting or inhibiting angiogenesis | |
US20220002360A1 (en) | Extracellular matrix protein compositions and methods for treating wounds | |
Wu et al. | Triamcinolone acetonide suppressed scar formation in mice and human hypertrophic scar fibroblasts in a dose-dependent manner | |
US20240245830A1 (en) | Multi-layer amniotic tissue grafts and uses thereof | |
CN117085137A (en) | IL-11 inhibitors and their use in anti-scarring therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |